Skip to content

Study · Observational study · n = 39 · 2022

6 results

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus.

Du J, Xi L, Zhang Z, Ge X, Li W, Peng W, Jiang X, Liu W, Zhao N, Wang X, Guo X, Huang S

Frontiers in endocrinology4 Jan 2023Cited by 8 (Europe PMC)

PMID36686441 (opens in a new tab)PMCIDPMC9846071 (opens in a new tab)DOI10.3389/fendo.2022.1097612 (opens in a new tab)PepBankPUB-36686441
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

AimsAs metabolic remodeling is a pathological characteristic in type 2 diabetes (T2D), we investigate the roles of newly developed long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as dulaglutide and liraglutide on metabolic remodeling in patients with recent-onset T2D.MethodsWe recruited 52 cases of T2D and 28 control cases in this study. In the patient with T2D, 39 cases received treatment with dulaglutide and 13 cases received treatment with liraglutide. Using untargeted metabolomics analysis with broad-spectrum LC-MS, we tracked serum metabolic changes of the patients from the beginning to the end of follow-up (12th week).ResultsWe identified 198 metabolites that were differentially expressed in the patients with T2D, compared to the control group, in which 23 metabolites were significantly associated with fasting plasma glucose. Compared to pre-treatment, a total of 46 and 45 differentially regulated metabolites were identified after treatments with dulaglutide and liraglutide, respectively, in which the most differentially regulated metabolites belong to glycerophospholipids. Furthermore, a longitudinal integration analysis concurrent with diabetes case-control status revealed that metabolic pathways, such as the insulin resistance pathway and type 2 diabetes mellitus, were enriched after dulaglutide and liraglutide treatments. Proteins such as GLP-1R, GNAS, and GCG were speculated as potential targets of dulaglutide and liraglutide.ConclusionsIn total, a metabolic change in lipids existed in the early stage of T2D was ameliorated after the treatments of GLP-1RAs. In addition to similar effects on improving glycemic control, remodeling of glycerophospholipid metabolism was identified as a signature of dulaglutide and liraglutide treatments.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyMechanism

    In recent-onset T2D, dulaglutide treatment changed 46 metabolites relative to pretreatment, predominantly glycerophospholipids.

    In plain wordsIn people with recent diabetes, dulaglutide changed metabolites compared with pretreatment, mainly glycerophospholipids.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    MixedDifferentially regulated metabolites
    Study

    n = 39

    Comparator
    Pre-treatment
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Differentially regulated metabolites
    46 metabolites
    dulaglutide

    Source sentences

    Summary
    Compared to pre-treatment, a total of 46 and 45 differentially regulated metabolites were identified after treatments with dulaglutide and liraglutide, respectively, in which the most differentially regulated metabolites belong to glycerophospholipids.
    2 context sentences
    Summary · context
    In the patient with T2D, 39 cases received treatment with dulaglutide and 13 cases received treatment with liraglutide.
    Summary · context
    Using untargeted metabolomics analysis with broad-spectrum LC-MS, we tracked serum metabolic changes of the patients from the beginning to the end of follow-up (12th week).
  2. 02HumanObservational studyMechanism

    In recent-onset T2D, liraglutide treatment changed 45 metabolites relative to pretreatment, predominantly glycerophospholipids.

    In plain wordsIn people with recent diabetes, liraglutide changed metabolites compared with pretreatment, mainly glycerophospholipids.

    Peptide
    Liraglutide
    Outcome
    MixedDifferentially regulated metabolites
    Study

    n = 13

    Comparator
    Pre-treatment
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Differentially regulated metabolites
    45 metabolites
    liraglutide

    Source sentences

    Summary
    Compared to pre-treatment, a total of 46 and 45 differentially regulated metabolites were identified after treatments with dulaglutide and liraglutide, respectively, in which the most differentially regulated metabolites belong to glycerophospholipids.
    2 context sentences
    Summary · context
    In the patient with T2D, 39 cases received treatment with dulaglutide and 13 cases received treatment with liraglutide.
    Summary · context
    Using untargeted metabolomics analysis with broad-spectrum LC-MS, we tracked serum metabolic changes of the patients from the beginning to the end of follow-up (12th week).

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 03Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoMechanism

    Computer integration of patient data identified insulin resistance and diabetes pathway enrichment after dulaglutide treatment.

    In plain wordsComputer analysis identified enriched insulin resistance and diabetes pathways after dulaglutide treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableMetabolic pathway enrichment
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Furthermore, a longitudinal integration analysis concurrent with diabetes case-control status revealed that metabolic pathways, such as the insulin resistance pathway and type 2 diabetes mellitus, were enriched after dulaglutide and liraglutide treatments.
    2 context sentences
    Summary · context
    In the patient with T2D, 39 cases received treatment with dulaglutide and 13 cases received treatment with liraglutide.
    Summary · context
    Using untargeted metabolomics analysis with broad-spectrum LC-MS, we tracked serum metabolic changes of the patients from the beginning to the end of follow-up (12th week).

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 04Computer modelNot a test of Liraglutide aloneIn silicoMechanism

    Computer integration of patient data identified insulin resistance and diabetes pathway enrichment after liraglutide treatment.

    In plain wordsComputer analysis identified enriched insulin resistance and diabetes pathways after liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    Not applicableMetabolic pathway enrichment
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Furthermore, a longitudinal integration analysis concurrent with diabetes case-control status revealed that metabolic pathways, such as the insulin resistance pathway and type 2 diabetes mellitus, were enriched after dulaglutide and liraglutide treatments.
    2 context sentences
    Summary · context
    In the patient with T2D, 39 cases received treatment with dulaglutide and 13 cases received treatment with liraglutide.
    Summary · context
    Using untargeted metabolomics analysis with broad-spectrum LC-MS, we tracked serum metabolic changes of the patients from the beginning to the end of follow-up (12th week).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 05Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoMechanism

    Computer analysis suggested GLP-1R, GNAS and GCG as potential dulaglutide targets.

    In plain wordsComputer analysis suggested GLP-1R, GNAS and GCG as possible dulaglutide targets.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicablePredicted protein targets
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Metabolic and weight

    Source sentences

    Summary
    Proteins such as GLP-1R, GNAS, and GCG were speculated as potential targets of dulaglutide and liraglutide.
    2 context sentences
    Summary · context
    In the patient with T2D, 39 cases received treatment with dulaglutide and 13 cases received treatment with liraglutide.
    Summary · context
    Using untargeted metabolomics analysis with broad-spectrum LC-MS, we tracked serum metabolic changes of the patients from the beginning to the end of follow-up (12th week).

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 06Computer modelNot a test of Liraglutide aloneIn silicoMechanism

    Computer analysis suggested GLP-1R, GNAS and GCG as potential liraglutide targets.

    In plain wordsComputer analysis suggested GLP-1R, GNAS and GCG as possible liraglutide targets.

    Peptide
    Liraglutide
    Outcome
    Not applicablePredicted protein targets
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Metabolic and weight

    Source sentences

    Summary
    Proteins such as GLP-1R, GNAS, and GCG were speculated as potential targets of dulaglutide and liraglutide.
    2 context sentences
    Summary · context
    In the patient with T2D, 39 cases received treatment with dulaglutide and 13 cases received treatment with liraglutide.
    Summary · context
    Using untargeted metabolomics analysis with broad-spectrum LC-MS, we tracked serum metabolic changes of the patients from the beginning to the end of follow-up (12th week).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.